CanadaBis CapitalTSXV:CANB EBIT per Share is C$-0.00 as of Oct. 2025. The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, CanadaBis Capital ranks worse than 89.12% on this metric.
CanadaBis Capital's EBIT per Share for the
three
months ended in Oct. 2025 was C$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2025 was C$-0.00.
During the past 12 months, the average EBIT per Share Growth Rate of CanadaBis Capital was -66.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -27.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CanadaBis Capital's EBIT per Share or its related term are showing as below:
TSXV:CANB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -41.5 Med: -27.9 Max: -20
Current: -27.9
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of CanadaBis Capital was -20.00% per year. The lowest was -41.50% per year. And the median was -27.90% per year.
TSXV:CANB's 3-Year EBIT Growth Rate is ranked worse than 89.12% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs TSXV:CANB: -27.90
CanadaBis Capital (TSXV:CANB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CanadaBis Capital EBIT per Share Related Terms
CanadaBis Capital EBIT per Share Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a EBIT per Share of C$-0.00 as of Oct. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CanadaBis Capital and its competitors. According to the industry distribution chart, CanadaBis Capital ranks #721 out of 809 companies in the Drug Manufacturers industry, placing it in the top 89.1%.
Is CanadaBis Capital's EBIT per Share too high?
CanadaBis Capital's current EBIT per Share is C$-0.00. Based on the distribution chart, CanadaBis Capital ranks #721 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CanadaBis Capital's EBIT per Share compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #721 out of 809 companies for EBIT per Share. This places CanadaBis Capital in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current EBIT per Share is C$-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current EBIT per Share of C$-0.00. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current EBIT per Share is C$-0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current EBIT per Share is C$-0.00 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 